Restricted accessResearch articleFirst published online 2018-10
Rapid effectiveness of intravenous ketamine for ultraresistant depression in a clinical setting and evidence for baseline anhedonia and bipolarity as clinical predictors of effectiveness
Intravenous ketamine has been established as an efficacious and safe treatment, with transient effect, for treatment-resistant depression. However, the effectiveness of intravenous ketamine in non-research settings and with ultraresistant depression patients remains understudied.
Aims:
This study aims to measure the response and remission rates in ultraresistant depression patients in a clinical setting by means of a retrospective, open label, database study. Secondarily, the study will attempt to support previous findings of clinical predictors of effectiveness with intravenous ketamine treatment.
Methods:
Fifty patients with ultraresistant depression were treated between May 2015–December 2016, inclusive, in two community hospitals in Edmonton using six ketamine infusions of 0.5 mg/kg over 40 min over 2–3 weeks. Data were collected retrospectively from inpatient and outpatient charts. Statistical analysis to investigate clinical predictors of effectiveness included logistic regression analysis using a dependent variable of a 50% reduction in rating scale score at any point during treatment.
Results:
At baseline, the average treatment resistance was severe, with a Maudsley Staging Method score of 12.1 out of 15, 90.0% were resistant to electroconvulsive therapy, and the average Beck Depression Inventory score was 34.2. The response rate was 44% and remission rate was 16%. As a single predictor, moderate or severe anhedonia at baseline predicted a 55% increased likelihood of response. As a combined predictor, this level of anhedonia at baseline with a diagnosis of bipolar depression predicted a 73% increase in likelihood of response.
Conclusion:
In a clinical setting, intravenous ketamine showed effectiveness in a complex, severely treatment-resistant, depressed population on multiple medication profiles concurrently. This study gave support to anhedonia and bipolar depression as clinical predictors of effectiveness.
AbdallahCGAdamsTGKelmendiBet al. (2016) Ketamine’s mechanism of action: A path to rapid-acting antidepressants. Depress Anxiety33: 689–697.
2.
AbdallahCGAverillLACollinsKAet al. (2017) Ketamine treatment and global brain connectivity in major depression. Neuropsychopharmacology42: 1210–1219.
3.
AnandACharneyDSOrenDAet al. (2000) Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: Support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists. Arch Gen Psychiatry57: 270–276.
4.
BallardEDIonescuDFVande VoortJLet al. (2014) Improvement in suicidal ideation after ketamine infusion: Relationship to reductions in depression and anxiety. J Psychiatr Res58: 161–166.
5.
BallardEDYarringtonJSFarmerCAet al. (2018) Parsing the heterogeneity of depression: An exploratory factor analysis across commonly used depression rating scales. J Affect Disord231: 51–57.
BeckATWardCHMendelsonMet al. (1961) An inventory for measuring depression. Arch Gen Psychiatry4: 561–571.
8.
BermanRMCappielloAAnandAet al. (2000) Antidepressant effects of ketamine in depressed patients. Biol Psychiatry47(4): 351–354
9.
BushGLuuPPosnerMI (2000) Cognitive and emotional influences in anterior cingulate cortex. Trends Cogn Sci4: 215–222.
10.
BushGVogtBAHolmesJet al. (2002) Dorsal anterior cingulate cortex: A role in reward-based decision making. Proc Natl Acad Sci USA99: 523–528.
11.
CohenASCoutureSMBlanchardJJ (2012) Neuropsychological functioning and social anhedonia: Three-year follow-up data from a longitudinal community high risk study. J Psychiatr Res46: 898–904.
12.
CoyleCMLawsKR (2015) The use of ketamine as an antidepressant: A systematic review and meta-analysis. Hum Psychopharmacol30: 152–163.
13.
DiazGranadosNIbrahimLABrutscheNEet al. (2010) Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder. J Clin Psychiatry71: 1605–1611.
14.
DoyleOMDe SimoniSSchwarzAJet al. (2013) Quantifying the attenuation of the ketamine pharmacological magnetic resonance imaging response in humans: A validation using antipsychotic and glutamatergic agents. J Pharmacol Exp Ther345:151–160.
DumanRS (2014) Pathophysiology of depression and innovative treatments: Remodeling glutamatergic synaptic connections. Dialogues Clin Neurosci16: 11–27.
17.
FawcettJScheftnerWAFoggLet al. (1990) Time-related predictors of suicide in major affective disorder. Am J Psychiatry147: 1189–1194.
18.
FekaduAWoodersonSDonaldsonCet al. (2009a) A multidimensional tool to quantify treatment resistance in depression: The Maudsley staging method. J Clin Psychiatry70: 177–184.
19.
FekaduAWoodersonSCMarkopoulouKet al. (2009b) The Maudsley Staging Method for treatment-resistant depression: Prediction of longer-term outcome and persistence of symptoms. J Clin Psychiatry70: 952–957.
20.
GrunebaumMFEllisSPKeilpJGet al. (2017) Ketamine versus midazolam in bipolar depression with suicidal thoughts: A pilot midazolam-controlled randomized clinical trial. Bipolar Disord19:176–183.
21.
HamiltonJPFurmanDJChangCet al. (2011) Default-mode and task-positive network activity in major depressive disorder: Implications for adaptive and maladaptive rumination. Biol Psychiatry70: 327–333.
22.
HamiltonM (1960) A rating scale for depression. J Neurol Neurosurg Psychiatry23: 56–62.
23.
IonescuDFLuckenbaughDANiciuMJet al. (2014) Effect of baseline anxious depression on initial and sustained antidepressant response to ketamine. J Clin Psychiatry75: e932–e938.
24.
KadriuBGoldPWLuckenbaughDAet al. (2017) Acute ketamine administration corrects abnormal inflammatory bone markers in major depression. Mol Psychiatry. doi: 10.1038/mp.2017.109.
25.
KennedySHLamRWMcIntyreRSet al. (2016) Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: Section 3. Pharmacological treatments. Can J Psychiatry61: 540–560.
26.
KesslerRC (2012) The costs of depression. Psychiatr Clin North Am35: 1–14.
27.
KesslerRC (2018) The potential of predictive analytics to provide clinical decision support in depression treatment planning. Curr Opin Psychiatry31: 32–39.
28.
KiralyDDHornSRvan DamNTet al. (2017) Altered peripheral immune profiles in treatment-resistant depression: Response to ketamine and prediction of treatment outcome. Transl Psychiatry7: 1–8.
29.
LallyNNugentACLuckenbaughDAet al. (2014) Anti-anhedonic effect of ketamine and its neural correlates in treatment-resistant bipolar depression. Transl Psychiatry4: e469.
30.
LehmannMSeifritzEHenningAet al. (2016) Differential effects of rumination and distraction on ketamine induced modulation of resting state functional connectivity and reactivity of regions within the default-mode network. Soc Cogn Affect Neurosci11: 1227–1235.
31.
LiNLeeBLiuR-Jet al. (2010) mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science329: 959–964.
32.
LuckenbaughDAIbrahimLBrutscheNet al. (2012) Family history of alcohol dependence and antidepressant response to an N-methyl-D-aspartate antagonist in bipolar depression. Bipolar Disord14: 880–887.
33.
Machado-VleiraRGoldPWLuckenbaughDAet al. (2017) The role of adipokines in the rapid antidepressant effects of ketamine. Mol Psychiatry22: 127–133.
MathewSJMurroughJWaan het RotMet al. (2010) Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: A pilot randomized, placebo-controlled continuation trial. Int J Neuropsychopharmacol13: 71–82.
36.
MaybergHSBrannanSKMahurinRKet al. (1997) Cingulate function in depression: A potential predictor of treatment response. Neuroreport8: 1057–1061.
37.
McInerneySJMcNeelyHEGeraciJet al. (2017) Neurocognitive predictors of response in treatment resistant depression to subcallosal cingulate gyrus deep brain stimulation. Front Hum Neurosci11: 74.
38.
McMakinDLOlinoTMPortaGet al. (2012) Anhedonia predicts poorer recovery among youth with selective serotonin reuptake inhibitor treatment-resistant depression. J Am Acad Child Adolesc Psychiatry51: 404–411.
39.
MontgomerySAAsbergM (1979) A new depression scale designed to be sensitive to change. Br J Psychiatry134: 382–389.
40.
MurroughJWIosifescuDVChangLCet al. (2013a) Antidepressant efficacy of ketamine in treatment-resistant major depression: A two-site randomized controlled trial. Am J Psychiatry170: 1134–1142.
41.
MurroughJWPerezAMPillemerSet al. (2013b) Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biol Psychiatry74: 250–256.
42.
NiciuMJMathewsDCIonescuDFet al. (2014) Biomarkers in mood disorders research: Developing new and improved therapeutics. Rev Psiquiatr Clin41: 131–134.
43.
NuttDDemyttenaereKJankaZet al. (2007) The other face of depression, reduced positive affect: The role of catecholamines in causation and cure. J Psychopharmacol21: 461–471.
44.
OverallJEGorhamDR (1962) The brief psychiatric rating scale. Psychol Rep10: 799–812.
45.
PennybakerSJNiciuMJLuckenbaughDAet al. (2017) Symptomatology and predictors of antidepressant efficacy in extended responders to a single ketamine infusion. J Affect Disord208: 560–566.
46.
PriceRBIosifescuDVMurroughJWet al. (2014) Effects of ketamine on explicit and implicit suicidal cognition: a randomized controlled trial in treatment-resistant depression. Depress Anxiety31(4): 335–343
47.
PrudicJHaskettRFMulsantBet al. (1996) Resistance to antidepressant medications and short-term clinical response to ECT. Am J Psychiatry153: 985–992.
48.
ReinstatlerLYoussefNA (2015) Ketamine as a potential treatment for suicidal ideation: A systematic review of the literature. Drugs R D15: 37–43.
49.
RongCParkCRosenblatJDet al. (2018) Predictors of response to ketamine in treatment resistant major depressive disorder and bipolar disorder. Int J Environ Res Public Health15: 1–10.
50.
SaliganLNLuckenbaughDASlonenaEEet al. (2016) An assessment of the anti-fatigue effects of ketamine from a double-blind, placebo-controlled, crossover study in bipolar disorder. J Affect Disord194: 115–119.
51.
SalvadoreGCornwellBRColon-RosarioVet al. (2009) Increased anterior cingulate cortical activity in response to fearful faces: A neurophysiological biomarker that predicts rapid antidepressant response to ketamine. Biol Psychiatry65: 289–295.
52.
SanacoraGFryeMAMcDonaldWet al. (2017) A consensus statement on the use of ketamine in the treatment of mood disorders. JAMA Psychiatry74: 399–405.
53.
SerafiniGHowlandRHRovediFet al. (2014) The role of ketamine in treatment-resistant depression: A systematic review. Curr Neuropharmacol12: 444–461.
54.
SheltonRCMillerAH (2011) Inflammation in depression: Is adiposity a cause?Dialogues Clin Neurosci13: 41–53.
55.
SpijkerJBijlRVde GraafRet al. (2001) Determinants of poor 1-year outcome of DSM-III-R major depression in the general population: Results of the Netherlands Mental Health Survey and Incidence Study (NEMESIS). Acta Psychiatr Scand103: 122–130.
56.
TrivediMHRushAJWisniewskiSRet al. (2006) Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: Implications for clinical practice. Am J Psychiatry163: 28–40.
57.
UherRPerlisRHHenigsbergNet al. (2012) Depression symptom dimensions as predictors of antidepressant treatment outcome: Replicable evidence for interest-activity symptoms. Psychol Med42: 967–980.
58.
UK ECT Review Group. (2003) Efficacy and safety of electroconvulsive therapy in depressive disorders: A systematic review and meta-analysis. Lancet361: 799–808.
59.
VosTBarberRMBellBet al. (2015) Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: A systematic analysis for the Global Burden of Disease Study 2013. Lancet386: 743–800.
60.
WackerJDillonDGPizzagalliDA (2009) The role of the nucleus accumbens and rostral anterior cingulate cortex in anhedonia: Integration of resting EEG, fMRI, and volumetric techniques. NeuroImage46: 327–337.
61.
WanL-BLevitchCFPerezAMet al. (2015) Ketamine safety and tolerability in clinical trials for treatment-resistant depression. J Clin Psychiatry76: 247–252.
62.
WangHJZakhariSJungMK (2010) Alcohol, inflammation, and gut-liver-brain interactions in tissue damage and disease development. World J Gastroenterol16: 1304–1313.
63.
WilkinsonSTBallardEDBlochMHet al. (2018) The effect of a single dose of intravenous ketamine on suicidal ideation: A systematic review and individual participant data meta-analysis. Am J Psychiatry175: 150–158.
ZarateCAJrBrutscheNEIbrahimLet al. (2012) Replication of ketamine’s antidepressant efficacy in bipolar depression: A randomized controlled add-on trial. Biol Psychiatry71: 939–946.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
